-
Phase 1 Open-Label Multicenter Dose Escalation Study of mRNA-2752 a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L IL-23 and IL-36? for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
The purpose of the study is to evaluate the anti-tumor activity of ITu injections of mRNA-2752 alone and in combination with intravenously administered durvalumab in ...Phase
Interventional
